Campora E, Oliva C, Mammoliti S, Cetto G L, Fosser V, Marangolo M, Rosso R
Dept. of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Breast Cancer Res Treat. 1991 Oct;19(2):129-32. doi: 10.1007/BF01980943.
The efficacy of the serotonin antagonist ondansetron (GR 38032F) was evaluated in the prevention of nausea and vomiting induced by CMF chemotherapy in 29 breast cancer patients. At their first treatment course of CMF, all given IV on day 1 q 21 days, patients were given oral antiemetic treatment as follows: ondansetron 8 mg, 2 h prior to CMF, repeated after 5 and 10 h the day of chemotherapy and then 8 mg tds for a minimum of 3 days to a maximum of 5 days following chemotherapy. At first course of CMF, complete protection from emesis and nausea was observed in 86.2% and 62% of patients, respectively. At subsequent CMF courses with ondansetron, complete control of emesis was observed in 80% of patients. Side effects were mild and no dystonic reactions were observed. Ondansetron represents an effective, safe, and easily administered outpatient regimen. The addition of a corticosteroid to ondansetron could further improve control of CMF-induced emesis.
在29例乳腺癌患者中评估了5-羟色胺拮抗剂昂丹司琼（GR 38032F）预防CMF化疗所致恶心和呕吐的疗效。在CMF的首个疗程中（所有患者均于第1天静脉注射，每21天1次），患者接受如下口服止吐治疗：在CMF化疗前2小时给予昂丹司琼8毫克，化疗当天5小时和10小时后重复给药，然后在化疗后至少3天至最多5天内每天3次，每次8毫克。在CMF的首个疗程中，分别有86.2%和62%的患者完全避免了呕吐和恶心。在后续使用昂丹司琼的CMF疗程中，80%的患者呕吐得到完全控制。副作用轻微，未观察到张力障碍反应。昂丹司琼是一种有效、安全且易于给药的门诊治疗方案。在昂丹司琼中添加一种皮质类固醇可进一步改善对CMF所致呕吐的控制。
